panel-7-defending-market-exclusivity-through-hatch

20 May 2026VideosAmericasHa Kung Wong, Venable | Sarah Fendrick, Alnylam Pharmaceuticals | Abby Markeson, Arcutis Biotherapeutics | Eberle Schultz, Sumitomo Pharma America

WATCH: Defending market exclusivity through Hatch-Waxman and BPCIA litigation strategies

The influx of biosimilars and generics requires innovator companies and challengers alike to continually refine their litigation tactics. This panel dissects current trends in Hatch-Waxman and BPCIA frameworks, providing a roadmap for defending franchises and navigating market entry.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

California votes for law to restrict use of genAI by lawyers

10x Genomics wins latest round in Parse patent dispute

Sun Pharma import ban back in force after Squires intervention

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Tempus AI bid to derail DNA patent case hits snag

Teva faces scrutiny over efforts to curb generic competition

WATCH: Defending market exclusivity through Hatch-Waxman and BPCIA litigation strategies

More on this story

Editor's picks

Editor's picks

More features